Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry

被引:24
作者
Venketasubramanian, Narayanaswamy [1 ]
Roether, Joachim [2 ]
Bhatt, Deepak L. [3 ,4 ]
Pasquet, Blandine [6 ]
Mas, Jean-Louis [7 ]
Alberts, Mark J. [5 ]
Hill, Michael D. [10 ]
Aichner, Franz [11 ]
Steg, P. Gabriel [8 ,9 ]
机构
[1] Natl Univ Singapore, Natl Univ Hlth Syst, Div Neurol, Singapore 119228, Singapore
[2] Asklepios Klin Altona, Dept Neurol, Hamburg, Germany
[3] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Hop Xavier Bichat, APHP, INSERM, CIE 801,Dept Epidemiol, Paris, France
[7] Paris Descartes Univ, INSERM U894, Hop St Anne, Dept Neurol, Paris, France
[8] Univ Paris 07, INSERM U698, Paris, France
[9] Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France
[10] Univ Calgary, Foothills Hosp, Dept Clin Neurosci, Calgary, AB, Canada
[11] Acad Teaching Hosp Wagner Jauregg, Linz, Austria
关键词
Atherothrombosis; Cerebrovascular disease; Epidemiology; Risk factors; Stroke; ARTERIAL ORIGIN ESPRIT; CEREBRAL-ISCHEMIA; RECURRENT STROKE; ASPIRIN; RISK; CLOPIDOGREL; DIPYRIDAMOLE; OUTPATIENTS; PREVENTION; MANAGEMENT;
D O I
10.1159/000328650
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose: Few practice-based studies have reported vascular outcome events among patients with cerebrovascular disease (CeVD). We describe 2-year vascular outcomes among symptomatic CeVD patients from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Methods: Vascular events (stroke; myocardial infarction, MI; cardiovascular death, CV death; hospitalization) were studied among symptomatic CeVD patients from a prospective cohort of stable outpatients with established atherothrombosis or >= 3 atherothrombotic risk factors. Results: Of the 69,055 patients in REACH, 18,992 (28%) had symptomatic CeVD, of which outcome data were available for 18,189 patients. At 2 years, the frequency of non-fatal stroke was 5.93% (95% CI 5.22-6.64), non-fatal MI 2.21% (95% CI 1.65-2.76), CV death 4.45% (95% CI 3.66-5.22), combined vascular endpoint 11.48% (95% CI 10.46-12.49), and all deaths 7.39% (95% CI 6.34-8.42). The frequency of stroke, MI, CV death, or hospitalization for atherothrombotic events was 21.05% (95% CI 20.05-22.03). Event rates were lowest among patients with CeVD alone and highest among patients with CeVD, coronary artery disease, and peripheral artery disease. Other predictors of the primary outcome were increasing age, history of diabetes, current smoking, asymptomatic carotid stenosis, and carotid plaque. Outcomes were similar across geographical regions. Conclusions: Symptomatic CeVD patients encounter high vascular event rates despite treatment. Recurrent nonfatal stroke is more common than nonfatal MI. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:254 / 260
页数:7
相关论文
共 21 条
[1]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[2]  
Antiplatelet Trialists' Collaboration, 1994, BMJ-BRIT MED J, V308, P81, DOI [DOI 10.1136/BMJ.308.6921.81, 10.1136/bmj.308.6921.81]
[3]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[4]   International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis [J].
Bhatt, DL ;
Steg, PG ;
Ohman, EM ;
Hirsch, AT ;
Ikeda, Y ;
Mas, JL ;
Goto, S ;
Liau, CS ;
Richard, AJ ;
Röther, J ;
Wilson, PWF ;
Andersen-Dalheim, H ;
Anderson, P ;
Anell, B ;
Arber, S ;
Armstrong, K ;
Arnot, D ;
Baldam, A ;
Barratt, I ;
Barresi, S ;
Beder, J ;
Benson, M ;
Bergman, F ;
Best, J ;
Bhasim, R ;
Bovell, G ;
Bowman, N ;
Brkic, M ;
Bromberger, D ;
Brown, D ;
Brown, J ;
Brownstein, M ;
Bruce, A ;
Buonopane, J ;
Burns, S ;
Butler, A ;
Byrne, D ;
Carson, J ;
Cassimatis, P ;
Chaffey, G ;
Chambers, D ;
Chan, WJ ;
Chan, B ;
Cheatham, J ;
Chen, R ;
Cheong, B ;
Cheung, C ;
Chin, J ;
Chiu, A ;
Choo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02) :180-189
[5]   Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attack [J].
Brown, DL ;
Lisabeth, LD ;
Roychoudhury, C ;
Ye, YN ;
Morgenstern, LB .
STROKE, 2005, 36 (06) :1285-1287
[6]   Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke [J].
Carolei, Antonio ;
Chamorro, Angel ;
Laloux, Patrice ;
Leys, Didier ;
Roether, Joachim ;
Sander, Dirk ;
Stansby, Gerard ;
Weimar, Christian .
INTERNATIONAL JOURNAL OF STROKE, 2008, 3 (04) :237-248
[7]   Recurrent stroke and cardiac risks after first ischemic stroke - The Northern Manhattan Study [J].
Dhamoon, MS ;
Sciacca, RR ;
Rundek, T ;
Sacco, RL ;
Elkind, MSV .
NEUROLOGY, 2006, 66 (05) :641-646
[8]   Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial [J].
Diener, HC ;
Bogousslavsky, J ;
Brass, LM ;
Cimminiello, C ;
Csiba, L ;
Kaste, M ;
Leys, D ;
Matias-Guiv, J ;
Rupprecht, HJ .
LANCET, 2004, 364 (9431) :331-337
[9]   Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial [J].
Halkes, P. H. A. ;
van Gijn, J. ;
Kappelle, L. J. ;
Koudstaal, P. J. ;
Algra, A. .
LANCET NEUROLOGY, 2007, 6 (02) :115-124
[10]  
Halkes PHA, 2006, LANCET, V367, P1665